Mikael J Eliasson

Title: The Innovative Contributions of Mikael J Eliasson

Introduction

Mikael J Eliasson is a notable inventor based in Baltimore, MD, who has made significant contributions to the field of neuroprotection. His work focuses on developing methods to prevent or treat neurotoxicity, particularly in relation to ischemia and reperfusion injury, as well as neurodegenerative diseases.

Latest Patents

Eliasson holds a patent for a method of using selective PARP inhibitors to prevent or treat neurotoxicity. This innovative approach involves administering therapeutically effective amounts of certain selective inhibitors of poly(ADP-ribose)polymerase. The inhibitors can be delivered through various methods, including intravenous, intraperitoneal, intramuscular, intraventricular, or oral routes. They can be formulated as capsules or tablets containing single or divided doses, or as sterile solutions, suspensions, or emulsions.

Career Highlights

Eliasson is affiliated with The Johns Hopkins University, where he continues to advance research in neuroprotection and therapeutic interventions. His work has the potential to significantly impact the treatment of conditions that lead to neurotoxicity.

Collaborations

Eliasson has collaborated with esteemed colleagues, including Kenji Sampei and Allen S Mandir, to further enhance the research and development of neuroprotective strategies.

Conclusion

Mikael J Eliasson's innovative work in the field of neuroprotection exemplifies the importance of research in developing effective treatments for neurotoxicity. His contributions are paving the way for advancements in medical science that could benefit many individuals suffering from neurodegenerative diseases.